David Livingston MD (chairman)
is deputy director and professor of medicine and genetics, Dana-Farber Cancer Institute, Harvard Medical School, USA, and a physician at Brigham and Womens Hospital, USA. He formerly was the chairman of the board of scientific advisors of the U.S. National Cancer Institute, USA. Among others, he is a member of the Institute of Medicine of the National Academy of Sciences, USA. He consults numerous oncology companies.

Karl-Heinz Altmann PhD
is professor of pharmaceutical sciences, Institute of Pharmaceutical Sciencies, Swiss Federal Institute of Technology (ETH) Zurich, Switzerland. Formerly, he was senior scientific expert chemistry, global head of Discovery Chemistry, member of the Novartis Pharma Research Management Board and head of the Scientific Chemistry Council, Novartis Ltd. He consults several companies.

William G. Kaelin MD
is a professor of medicine, Harvard Medical School, USA. He also is a member of the board of scientific advisors of the National Cancer Institute, USA, of the National Cancer Policy Board, Institute of Medicine, USA, and of the board of directors of the American Association for Cancer Research. He is involved with consultancy of several oncology companies.

Bruce A.J. Ponder PhD, FRCP, FRCPath, FMedSci, FRS
is the Cancer Research UK professor of oncology and head of the Department of Oncology, Cambridge University, UK. He is co-director of the Hutchison/MRC Research Institute & Strangeways Research Laboratories, UK and director of the new Cambridge University (Hutchison) Cancer Research UK Institute. Among others, he is a fellow of the Royal Society of London and of the Royal College of Physicians. He also consults for oncology companies.

Charles L. Sawyers MD
is the chair of the Human Oncology and Pathogenesis Program affiliated with the Memorial Sloan-Kettering Cancer Center, New York, USA. He is also the past president of the American Society of Clinical Investigation, served on the National Cancer Institute's Board of Scientific Councillors, and is a member of the Institute of Medicine and the National Academy of Sciences. He is a co-founder of Agensys, Inc. and involved with consultancy of several oncology companies.

Paul Workman PhD DSc (Hon) FMedSci
is the Director and Section Chair of the Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK, which is affiliated to the Royal Marsden Hospital. He is also the Harrap Professor of Pharmacology and Therapeutics, The Institute of Cancer Research and a Fellow of the Academy of Medical Sciences. Formerly, he was the Biology Section Head of Cancer Research, AstraZeneca Ltd. He is scientific founder of two oncology companies and consults for several others.